Eye treatment company KalVista Pharmaceuticals won the backing of Novo and SV Life Sciences in its spin off from Vantia Therapeutics. The two venture firms also backed Vantia's founding in 2008.
Denmark-based foundation Novo’s corporate venturing-style unit has helped UK-based healthcare company KalVista Pharmaceuticals, which treats an eye condition linked to diabetes, raise £8m ($13.2m).
Novo was joined in the series A round by venture firm SV Life Sciences to back KalVista, which is researching treatments of a disease of the eye caused by diabetes, called diabetic macular edema.
KalVista bought the intellectual property for its treatments from UK-based drug development company Vantia Therapeutics, from which it span out. KalVista’s…
